Concepts (154)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glucuronosyltransferase | 8 | 2020 | 25 | 3.620 |
Why?
|
| Prostatic Neoplasms | 16 | 2022 | 794 | 2.130 |
Why?
|
| Ovarian Neoplasms | 3 | 2019 | 303 | 1.180 |
Why?
|
| Receptors, Calcitriol | 2 | 2019 | 59 | 1.090 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2019 | 638 | 0.840 |
Why?
|
| DNA Methylation | 1 | 2020 | 301 | 0.610 |
Why?
|
| Polymorphism, Genetic | 3 | 2012 | 165 | 0.570 |
Why?
|
| Logistic Models | 8 | 2019 | 894 | 0.510 |
Why?
|
| Veterans | 4 | 2017 | 115 | 0.490 |
Why?
|
| Glucuronides | 1 | 2012 | 10 | 0.450 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2012 | 40 | 0.440 |
Why?
|
| Middle Aged | 17 | 2019 | 9642 | 0.380 |
Why?
|
| Peritoneal Neoplasms | 1 | 2010 | 15 | 0.370 |
Why?
|
| Genetic Variation | 1 | 2012 | 328 | 0.370 |
Why?
|
| Case-Control Studies | 8 | 2017 | 1056 | 0.370 |
Why?
|
| Aged | 15 | 2018 | 6448 | 0.360 |
Why?
|
| Minor Histocompatibility Antigens | 2 | 2020 | 8 | 0.320 |
Why?
|
| Humans | 27 | 2022 | 34853 | 0.310 |
Why?
|
| Risk Factors | 10 | 2017 | 3414 | 0.300 |
Why?
|
| Male | 20 | 2022 | 18870 | 0.300 |
Why?
|
| Body Mass Index | 4 | 2018 | 775 | 0.290 |
Why?
|
| Genetic Association Studies | 2 | 2019 | 102 | 0.290 |
Why?
|
| Genotype | 5 | 2012 | 641 | 0.270 |
Why?
|
| Exercise | 3 | 2018 | 524 | 0.260 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2004 | 9 | 0.250 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 2004 | 5 | 0.250 |
Why?
|
| Blood | 1 | 2004 | 32 | 0.250 |
Why?
|
| Gene Deletion | 1 | 2004 | 156 | 0.240 |
Why?
|
| Odds Ratio | 5 | 2012 | 517 | 0.240 |
Why?
|
| Isoenzymes | 2 | 2017 | 149 | 0.210 |
Why?
|
| Promoter Regions, Genetic | 1 | 2004 | 484 | 0.210 |
Why?
|
| Bayes Theorem | 1 | 2019 | 91 | 0.170 |
Why?
|
| Retrospective Studies | 5 | 2017 | 1961 | 0.170 |
Why?
|
| Alleles | 2 | 2012 | 284 | 0.160 |
Why?
|
| Dihydrotestosterone | 1 | 2017 | 26 | 0.160 |
Why?
|
| Biopsy | 5 | 2018 | 151 | 0.160 |
Why?
|
| Recurrence | 1 | 2017 | 125 | 0.150 |
Why?
|
| Benzidines | 2 | 2007 | 8 | 0.150 |
Why?
|
| Erectile Dysfunction | 1 | 2017 | 26 | 0.150 |
Why?
|
| Vitamin D | 1 | 2019 | 176 | 0.150 |
Why?
|
| Waist Circumference | 1 | 2017 | 82 | 0.150 |
Why?
|
| Diet | 2 | 2014 | 747 | 0.140 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2007 | 63 | 0.140 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 423 | 0.140 |
Why?
|
| Xenobiotics | 1 | 2015 | 10 | 0.140 |
Why?
|
| Adiposity | 1 | 2017 | 145 | 0.140 |
Why?
|
| Microsomes, Liver | 1 | 2015 | 69 | 0.130 |
Why?
|
| Dietary Carbohydrates | 1 | 2014 | 30 | 0.130 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 859 | 0.130 |
Why?
|
| Disease Progression | 1 | 2017 | 580 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 781 | 0.130 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 964 | 0.130 |
Why?
|
| Female | 6 | 2019 | 19873 | 0.130 |
Why?
|
| Gene Expression | 1 | 2017 | 639 | 0.120 |
Why?
|
| North Carolina | 2 | 2014 | 103 | 0.120 |
Why?
|
| Linkage Disequilibrium | 1 | 2013 | 58 | 0.120 |
Why?
|
| Alopecia | 1 | 2013 | 9 | 0.120 |
Why?
|
| Homozygote | 1 | 2012 | 75 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 455 | 0.100 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2011 | 9 | 0.100 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2011 | 11 | 0.100 |
Why?
|
| Calcium, Dietary | 1 | 2012 | 83 | 0.100 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2011 | 36 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 528 | 0.100 |
Why?
|
| Carcinoma | 1 | 2011 | 94 | 0.090 |
Why?
|
| Diabetes Mellitus | 2 | 2017 | 465 | 0.090 |
Why?
|
| Receptors, Interleukin-8A | 1 | 2009 | 9 | 0.090 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2009 | 20 | 0.090 |
Why?
|
| Prostate-Specific Antigen | 2 | 2022 | 95 | 0.090 |
Why?
|
| Interleukin-8 | 1 | 2009 | 59 | 0.090 |
Why?
|
| Psychodrama | 1 | 2009 | 4 | 0.090 |
Why?
|
| Arylamine N-Acetyltransferase | 2 | 2006 | 24 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2018 | 1422 | 0.080 |
Why?
|
| Women's Health | 1 | 2009 | 135 | 0.080 |
Why?
|
| Acetyltransferases | 1 | 2007 | 26 | 0.080 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 92 | 0.080 |
Why?
|
| Base Sequence | 2 | 2004 | 932 | 0.070 |
Why?
|
| Occupational Exposure | 1 | 2006 | 67 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2004 | 3 | 0.060 |
Why?
|
| Pregnancy | 1 | 2010 | 1503 | 0.060 |
Why?
|
| Gene Frequency | 1 | 2004 | 155 | 0.060 |
Why?
|
| Chromosome Segregation | 1 | 2004 | 40 | 0.060 |
Why?
|
| Urine | 1 | 2004 | 9 | 0.060 |
Why?
|
| Endogenous Retroviruses | 1 | 2003 | 16 | 0.060 |
Why?
|
| Enzymes | 1 | 2004 | 30 | 0.060 |
Why?
|
| Salmonella typhimurium | 1 | 2004 | 40 | 0.060 |
Why?
|
| Meat | 1 | 2004 | 41 | 0.060 |
Why?
|
| Mutagenesis | 1 | 2004 | 87 | 0.060 |
Why?
|
| Introns | 1 | 2003 | 67 | 0.060 |
Why?
|
| DNA Primers | 1 | 2004 | 269 | 0.060 |
Why?
|
| Blood Proteins | 1 | 2003 | 65 | 0.060 |
Why?
|
| Hot Temperature | 1 | 2004 | 120 | 0.060 |
Why?
|
| Antigens, Neoplasm | 1 | 2003 | 56 | 0.060 |
Why?
|
| Health Promotion | 1 | 2009 | 588 | 0.060 |
Why?
|
| Gene Expression Regulation | 2 | 2009 | 968 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 790 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 2014 | 60 | 0.050 |
Why?
|
| Adult | 2 | 2010 | 11034 | 0.050 |
Why?
|
| Prostate | 1 | 2022 | 136 | 0.050 |
Why?
|
| Obesity | 2 | 2022 | 965 | 0.050 |
Why?
|
| Young Adult | 1 | 2010 | 4012 | 0.050 |
Why?
|
| Incidence | 2 | 2013 | 882 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2009 | 1426 | 0.040 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2017 | 14 | 0.040 |
Why?
|
| Acetylation | 2 | 2007 | 94 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2017 | 99 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 570 | 0.030 |
Why?
|
| Benzhydryl Compounds | 1 | 2015 | 42 | 0.030 |
Why?
|
| Glycemic Index | 1 | 2014 | 8 | 0.030 |
Why?
|
| United States | 2 | 2017 | 3894 | 0.030 |
Why?
|
| Phenols | 1 | 2015 | 76 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 256 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 1007 | 0.030 |
Why?
|
| Digital Rectal Examination | 1 | 2013 | 4 | 0.030 |
Why?
|
| Age of Onset | 1 | 2013 | 98 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2015 | 897 | 0.030 |
Why?
|
| Androgens | 1 | 2013 | 87 | 0.030 |
Why?
|
| Animals | 4 | 2015 | 14307 | 0.030 |
Why?
|
| Phenotype | 2 | 2006 | 650 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 1530 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 151 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2011 | 91 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2009 | 2128 | 0.020 |
Why?
|
| Smoking | 1 | 2017 | 903 | 0.020 |
Why?
|
| Mice | 2 | 2015 | 5668 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 531 | 0.020 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2009 | 21 | 0.020 |
Why?
|
| Neutrophil Infiltration | 1 | 2009 | 26 | 0.020 |
Why?
|
| Dimerization | 1 | 2009 | 102 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2009 | 51 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2013 | 1353 | 0.020 |
Why?
|
| Neutrophils | 1 | 2009 | 124 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 120 | 0.020 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2007 | 33 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2009 | 207 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2006 | 27 | 0.020 |
Why?
|
| Cell Line | 1 | 2009 | 1289 | 0.020 |
Why?
|
| China | 1 | 2006 | 178 | 0.020 |
Why?
|
| Health Behavior | 1 | 2009 | 491 | 0.020 |
Why?
|
| Kinetics | 1 | 2006 | 650 | 0.020 |
Why?
|
| Mutagenicity Tests | 1 | 2004 | 21 | 0.020 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 2003 | 22 | 0.020 |
Why?
|
| Haptoglobins | 1 | 2003 | 9 | 0.020 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2004 | 21 | 0.020 |
Why?
|
| Mutagenesis, Insertional | 1 | 2003 | 32 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2003 | 82 | 0.010 |
Why?
|
| Mutagens | 1 | 2004 | 66 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2006 | 727 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2003 | 286 | 0.010 |
Why?
|
| Cattle | 1 | 2004 | 472 | 0.010 |
Why?
|
| Rats | 1 | 2009 | 3261 | 0.010 |
Why?
|
| RNA | 1 | 2003 | 234 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2003 | 608 | 0.010 |
Why?
|
| Liver | 1 | 2003 | 447 | 0.010 |
Why?
|